SOURCE: Medpace


April 25, 2012 10:33 ET

Medpace Announces the Addition of Cheri Lindberg, MD, Medical Director, Strengthening Medpace's Therapeutic and Regulatory Expertise in Psychiatry

CINCINNATI, OH--(Marketwire - Apr 25, 2012) - Medpace, Inc. today announced the addition of Cheri Lindberg MD, as a Medical Director in the area of Psychiatry. Dr. Lindberg is a board certified psychiatrist who has been active in clinical and academic practice. Dr. Lindberg was most recently a Clinical Reviewer with the FDA, Center for Drug Evaluation and Research (CDER). As the newest addition to the Medpace team charged with design and conduct of clinical trials in the central nervous system, Dr. Lindberg's experience spanning regulatory and private practice will add to Medpace's capabilities in the growing area of CNS drug development.

"Cheri Lindberg brings another facet to our CNS group," said Jonathan Isaacsohn, MD, FACC, Executive Vice President. "Dr. Lindberg's background as a psychiatrist adds therapeutic depth for our Sponsors to conduct studies across a wide range of disorders. Combining that knowledge with her expertise as a former FDA reviewer builds Medpace's ability to address regulatory issues for our customers."

Dr. Lindberg received her Doctor of Medicine degree from Marshall University, School of Medicine, and also holds a Certificate of Public Health from Georgetown University in Washington, DC.

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at